Index

Note: Page numbers of article titles are in boldface type

A
Acute HCV infection, 995–1010. See Hepatitis C virus (HCV) infection, acute
Algorithms
   in staging of liver disease in chronic HCV, 856
   treatment
      in response-guided therapy for treatment-naive patients with genotype 1 chronic HCV infection, 896–898
Anemia
   INF-α/RBV for HCV infection and, 920–921
   management of treatment-naive patient with genotype 1 chronic HCV infection and, 899
Antibiotic(s)
   in gastrointestinal bleed prevention in cirrhosis, 983
APRI. See Aspartate aminotransferase/platelet ratio index (APRI)
Ascites
   cirrhosis and, 982–983
Aspartate aminotransferase/platelet ratio index (APRI)
   in staging of liver disease in chronic HCV, 851–852
Autoimmune system
   INF-α/RBV for HCV infection effects on, 925–926

B
Bacterial infections
   cirrhosis and, 983–984
Biomarkers
   for fibrosis in HCV
      future development of, 853–854
Blood tests
   in staging of liver disease in chronic HCV, 851
Boceprevir
   for HCV in HIV-infected patients, 936–938
      HIV drug interactions with, 940–941
   for treatment-naive patient with genotype 1 chronic HCV infection
      published studies, 894–895
Boceprevir triple therapy
   for HCV, 884–886
Breath tests
   in staging of liver disease in chronic HCV, 855

C
Cardiovascular system
   INF-α/RBV for HCV infection effects on, 924
Cirrhosis, 979–994
  care of patient with, 979–994
  complications of, 980–985
    ascites, 982–983
    bacterial infections, 983–984
    gastrointestinal bleed
      antibiotic prophylaxis in, 983
    hepatic encephalopathy, 984
    hepatocellular carcinoma, 984–985
    varices, 981–982
  decompensated, 980–981
  described, 979–980
  evaluation of, 980
  HCV infection in
    treatment of, 985–987
    treatment-experienced patient with genotype 1 chronic HCV infection and, 908–909
    response-guided therapy for
      contraindications to, 910–912
    treatment of
      liver transplantation in, 987
Cyclophilin A inhibitors
  for HCV infection, 958

D
DAA agents. See Direct-acting antiviral (DAA) agents
Direct-acting antiviral (DAA) agents
  for HCV
    described, 883
    in HIV patients, 931–948. See also Hepatitis C virus (HCV) infection, treatment of, in HIV patients, DAA therapy in
      monotherapy, 883–884
    rapid viral suppression in era of, 879–891. See also Rapid viral suppression, in era of DAA agents for HCV
Drug resistance
HCV, 967–978
  baseline resistance variants and response to therapy, 970–971
  in clinical practice, 971
  decay of resistant variants after treatment cessation, 970
  future research related to, 973–974
  IFN-free therapies and, 973
  novel antiviral agents, 971–973
  potential for, 967–968
  prevention of
    RBV in, 970
  questions related to, 973–974
  resistance to Peg-IFN/RBV, 969
  testing for, 971
  variants in
    persistence of, 968
  viral reservoirs and, 968
virology related to, 967–968
in vitro and clinical data, 968–969
Drug–drug interactions
INF-α/RBV for HCV infection and, 926

E
Early null response
in HCV therapy, 882–883
Encephalopathy(ies)
  hepatic
cirrhosis and, 984

F
Fatigue
INF-α/RBV for HCV infection and, 919–920
FIB-4
  in staging of liver disease in chronic HCV infection, 852
Fibropanca algorithm
  in staging of liver disease in chronic HCV infection, 856
FibroScan
  in staging of liver disease in chronic HCV infection, 854–855
Fibrosis(es)
in HCV
  biomarkers for
    future development of, 853–854
FibroTest
  in staging of liver disease in chronic HCV infection, 852
Flulike symptoms
INF-α/RBV for HCV infection and, 919
Forns index
  in staging of liver disease in chronic HCV infection, 852

G
Gastrointestinal bleed
  cirrhosis and
    antibiotic prophylaxis in, 983
Gastrointestinal system
INF-α/RBV for HCV infection effects on, 925
  management of treatment-naïve patient with genotype 1 chronic HCV infection effects
    on, 899–900
Genome-wide association studies (GWAS)
in detecting host genetic factors in HCV linking IL-28β to treatment response, 864–865
Genotype 1 chronic hepatitis C virus (HCV) infection
  early viral response in
    HCV therapy related to, 882
treatment-experienced patient with
  approach to, 903–915
    boceprevir
Genotype (continued)

- nonrandomized studies, 907
- randomized controlled trials, 905–907
- cirrhosis and, 908–909
- Peg-IFN/RBV, 908–909
- prior null response to, 911–912
- prior partial response to, 910–911
- prior relapse with, 909–910
- unknown prior response to, 912–913
- telaprevir
  - nonrandomized studies, 908
  - randomized controlled trials, 907–908
  - treat now or wait for better therapies, 913–914
- described, 903–904
- prevalence of, 903
- treatment-naïve patient with
  - approach to, 893–901
    - adverse effects of, 899–900
    - boceprevir
      - published studies of, 894–895
    - IL28-β, 898–899
    - PI combination therapy
      - eligibility for, 893–894
      - response-guided therapy, 896–898
      - safety issues in, 899–900
    - telaprevir
      - published studies, 895–896
      - treatment algorithms, 896–897
      - viral resistance, 897–898

GWAS. See Genome-wide association studies (GWAS)

H

HCV. See Hepatitis C virus (HCV)

Hepatic encephalopathy
- cirrhosis and, 984

Hepatitis C virus (HCV)
- background of, 879–880
- causes of, 879
- described, 863–864
- fibrosis in
  - biomarkers for
    - future development of, 853–854
  - life cycle of, 950–952
  - prevalence of, 849, 863
    - increase in, 842
  - virology of, 950–952
    - drug resistance potential related to, 967–968

Hepatitis C virus (HCV) infection
- acute, 995–1010
  - described, 995–996
diagnosis of, 997–998
epidemiology of, 996–997
natural course of, 998–999
risk factors for, 996
treatment of, 999–1002
duration of, 1002
initiation of, 999–1000
type of, 1000–1001
chronic
  genotype 1
    treatment-experienced patient with
      approach to, 903–915. See also Genotype 1 chronic hepatitis C virus (HCV) infection, treatment-experienced patient with, approach to
    treatment-naïve patient with
      approach to, 893–901. See also Genotype 1 chronic hepatitis C virus (HCV) infection, treatment-naïve patient with, approach to
staging of liver disease in, 849–861
  algorithms in, 856
  current recommendations for, 849–850
  imaging studies in, 854–855
  liver biopsy in, 850
  noninvasive markers in, 850–853
    comparisons among, 853
cirrhosis with
  treatment of, 985–987
liver disease vs. infectious disease, 839–841
staging of liver disease in
  implications of, 856–857
treatment of
  for advanced liver disease with thrombocytopenia, 943–944
  combination therapy in
    INF-α/RBV
      adverse effects of, 917–929. See also Interferon-α (INF-α)/RBV combination therapy, for HCV infection, adverse effects of
complexity and intensity of
  effects on provider resources, 842–843
DAA agents in
  alternate IFNs, 957–958
  NNIs of HCV polymerase, 955–957
  NS3/4A serine PIs, 952–953
  NS5A inhibitors, 957
  NS5B RdRp inhibitors, 953
  nucleos(t)ide inhibitors, 953–955
  rapid viral suppression in era of, 879–891. See also Rapid viral suppression, in era of DAA agents for HCV
  delivery of
    improvements in, 843
don drug resistance to, 967–978. See also Drug resistance, HCV
  future drug classes, 949–966
in HIV patients
  in DAA era, 931–948
Hepatitis C (continued)
   DAA therapy in, 933–934
   drug–drug interactions, 939–941
   evaluation of, 935
   future prospects for, 944–945
   no cross-activity or cross-resistance in, 939
   predictors of response to, 935
   telaprevir, 935–936
   triple therapy limitations, 938
   drug resistance, 941–942
   HIV therapy and, 880
   host-targeted agents in, 958–959
      cyclophilin A inhibitors, 958
      HMG CoA reductase inhibitors, 959
      miRNA122 inhibitors, 959
   infectious disease physicians in, 839–847
      gaining experience, 844–845
      integration into practices, 845
      preparation for, 844–845
      reasons for, 843–844
   in patients with liver transplants, 944
   prevalence of, 841–842
   in prior nonresponders to INF-α, 943
   response to
      described, 864
      IL-28β polymorphisms as pretreatment predictor of, 863–877. See also Interleukin-28β polymorphisms, as pretreatment predictor of HCV treatment response
   in special HIV/HCV patient populations, 942–944

Hepatocellular carcinoma
   cirrhosis and, 984–985

HIV (human immunodeficiency virus) infection
   HCV infection in patients with
      in DAA era
         treatment of, 931–948. See also Hepatitis C virus (HCV) infection, treatment of, in HIV patients, DAA therapy in
      liver disease associated with, 931–932
      treatment of
         in understanding of HCV therapy, 880
   HMG CoA reductase inhibitors
      for HCV infection, 959

Hypersensitivity reactions
   INF-α/RBV for HCV infection and, 927

I

IFN. See Interferon (IFN)

INF-α. See Interferon-α (INF-α)

Infection(s). See specific types

Infectious disease physicians
   care of HCV patients by, 839–847. See also Hepatitis C virus (HCV) infection, treatment of, infectious disease physicians in
Interferon (IFN)
alternate for HCV infection, 957–958
in HCV therapy
viral kinetics and, 880–881
type III
in clinical trials of HCV treatment
biology, function, and clinical application of, 865

Interferon (IFN)-free therapies
for HCV, 888
HCV resistance and, 973

Interferon (INF)/RBV combination therapy
viral kinetics with
in HCV therapy, 880

Interferon-α (INF-α)
pathophysiology of, 918
prior nonresponders to
HIV/HCV treatment for, 943

Interferon-α (INF-α)/RBV combination therapy for HCV infection
adverse effects of, 917–929
anemia, 920–921
autoimmune complications, 925–926
cardiocirculatory complications, 924
dermatologic complications, 923–924
drug–drug interactions, 926
fatigue, 919–920
flulike symptoms, 919
gastrointestinal complications, 925
hematologic complications, 920–922
hypersensitivity reactions, 927
neutropenia, 922
ophthalmologic complications, 923
psychiatric complications, 922–923
pulmonary complications, 924
systemic complications, 918–920
teratogenicity, 926
thrombocytopenia, 921–922
weight loss, 920

Interleukin-28β
in treatment-naïve patient with genotype 1 chronic HCV infection, 898–899

Interleukin-28β polymorphisms
genotyping of
for acute genotype 1 infection, 867–868
for chronic genotype 1 infection
in DAA era, 868–870
as pretreatment predictor of HCV treatment response, 863–877
GWAS in detection of, 864–865
homozygosity for favorable allele linked to rapid virologic response, 866
potential use in liver transplantation, 867
Interleukin-28β (continued)
  predictive value in non–genotype 1 infection, 866–867
  predictive value in special populations, 867
  type III IFN in clinical trials, 865

L
Leroy algorithm
  in staging of liver disease in chronic HCV infection, 856
Liver disease
  in HIV patients, 931–932
  staging of HCV in, 849–861. See also Hepatitis C virus (HCV) infection, chronic, staging of liver disease in
Liver transplantation
  in cirrhosis, 987
  for HCV
    IL-28β in
      predictive value of, 867
    HCV treatment in patients with, 944

M
Magnetic resonance imaging (MRI)
  in staging of liver disease in chronic HCV infection, 855
miRNA122 inhibitors
  for HCV infection, 959
MRI. See Magnetic resonance imaging (MRI)

N
Neutropenia
  INF-α/RBV for HCV infection and, 922
NNIs. See Nonnucleoside inhibitors (NNIs)
Nonnucleoside inhibitors (NNIs)
  of HCV polymerase
    for HCV infection, 955–957
NS3/4A serine protease inhibitors
  for HCV infection, 952–953
NS5A inhibitors
  for HCV infection, 957
NS5B RdRp inhibitors
  for HCV infection, 953
Nucleos(t)ide inhibitors
  for HCV infection, 953–955

O
Ocular system
  INF-α/RBV for HCV infection effects on, 923
P

Peg-IFN. See Pegylated interferon (Peg-IFN)
Pegylated interferon (Peg-IFN)
   for treatment-experienced patient with genotype 1 chronic HCV infection
      prior relapse with, 909–910
Pegylated interferon (Peg-IFN)/RBV combination therapy
   PI resistance with, 969
   for treatment-experienced patient with genotype 1 chronic HCV infection, 908–909
      approach to
         prior null response to, 911–912
         prior partial response to, 910–911
         unknown prior response to, 912–913
Peritonitis
   spontaneous bacterial
      cirrhosis and, 982–983
Pl. See Protease inhibitor(s) (PI)
Polymorphism(s)
   IL-28β
      as pretreatment predictor of HCV treatment response, 863–877. See also
         Interleukin-28β polymorphisms, as pretreatment predictor of HCV treatment response
Protease inhibitor(s) (PI)
   HCV
      resistance to, 968–969
      resistance to
         in combination with Peg-IFN/RBV, 969
         for treatment-naïve patient with genotype 1 chronic HCV infection
            combination therapy
               eligibility for, 893–894
PROVE 2 trial
   with telaprevir for HCV infection, 884
PROVE 3 trial, 887
Psychiatric system
   INF-α/RBV for HCV infection effects on, 922–923
Pulmonary system
   INF-α/RBV for HCV infection effects on, 924

R

Rapid viral suppression
   in era of DAA agents for HCV, 879–891. See also specific drugs
      boceprevir, 885–886
      boceprevir triple therapy, 884–886
      early null response, 882–883
      early virologic response, 881
      future implications for, 888
      in genotype 1, 882
      INF-free therapy, 888
      response-guided triple therapy, 884–885
      stopping rules in, 886
Rapid (continued)
  in treatment-experienced patients, 886–888
  viral assays in, 886
  viral kinetics as response measurement, 880
  viral kinetics with DAA monotherapy, 883–884
REALIZE trial, 887
RESPOND-2 trial, 887–888
Response-guided therapy
  for treatment-naïve patients with genotype 1 chronic HCV infection, 896–898
Response-guided triple therapy
  for HCV, 884–885
Ribavirin (RBV)
  INF-α with
    for HCV infection
      adverse effects of, 917–929. See also Interferon-α (INF-α)/RBV combination therapy, for HCV infection, adverse effects of pathophysiology of, 918
  Peg-IFN with
    for treatment-experienced patient with genotype 1 chronic HCV infection. See Pegylated interferon (Peg-INF)/RBV combination therapy in prevention of drug resistance development in HCV, 970

S
SAFE biopsy
  in staging of liver disease in chronic HCV infection, 856
Safety issues
  in management of treatment-naïve patient with genotype 1 chronic HCV infection, 899–900
SBP. See Spontaneous bacterial peritonitis (SBP)
Skin
  INF-α/RBV for HCV infection effects on, 923–924
Spontaneous bacterial peritonitis (SBP)
  cirrhosis and, 982–983
SPRINT-2 trial
  with boceprevir, 885–886
Sustained virologic response (SVR)
  defined, 949
SVR. See Sustained virologic response (SVR)

T
Telaprevir
  for HCV, 884–885
    clinical trials of, 883–884
    in HIV patients, 935–936
      HIV drug interactions with, 940
    for treatment-naïve patient with genotype 1 chronic HCV infection
      published studies, 895–896
Teratogenicity
  of INF-α/RBV for HCV infection, 926
Thrombocytopenia
   advanced liver disease with
      HIV/HCV treatment for, 943–944
      INF-α/RBV for HCV infection and, 921–922
Transplantation
   liver. See Liver transplantation

U
Ultrasound
   in staging of liver disease in chronic HCV infection, 854–855

V
Varice(s)
   cirrhosis and, 981–982
Viral kinetics
   in HCV therapy
      INF-based therapy, 880–881
      INF/RBV, 880
         as response measurement, 880
   in HIV therapy, 880

W
Weight loss
   INF-α/RBV for HCV infection and, 920